Ruiming Li: Why the COMBO Plus form is a Masterclass in Vascular Repair
Ruiming Li, Strategic Partnerships Development Professional at Curalife, shared a post on LinkedIn:
“The ‘Pro-healing’ disruptor: Why the COMBO Plus form is a Masterclass in Vascular Repair.
Most giants in Cath Lab focus on Mechanical Force.
But OrbusNeich Medical Company Ltd. is winning by focusing on Accelerated Biological Healing.
As your China MedTech Observer, I’m peeling back the layers of the COMBO Plus Dual Therapy Stent.
It’s not just a scaffold; it’s a bio-engineered environment designed to repair the artery from the inside out.
1. Dual therapy:
The ‘Sirolimus plus Antibody’ Synergy
Standard Drug-Eluting Stents (DES) rely on a single defensive move: blocking tissue growth. COMBO Plus plays offense and defense simultaneously:
Defense (Sirolimus Elution):
It uses a Bioabsorbable Polymer on the abluminal side to deliver Sirolimus.
This controls neointimal hyperplasia (restenosis) while ensuring no permanent polymer is left behind to cause long-term inflammation.
Offense (Genous™ Technology):
A world-first circumferential Anti-CD34 Antibody coating.
This acts as a ‘biological magnet,’ capturing Endothelial Progenitor Cells (EPCs) directly from the bloodstream.
The Result:
Instead of waiting months for a ‘dead’ metal surface to be covered, the COMBO Plus proactively recruits the body’s own cells to form a functional endothelial layer.
2. Clinical validation: Short DAPT and Safety
The COMBO platform is backed by a massive clinical footprint, including the Reduce and Harmonee trials.
The reduce Trial: Demonstrated that in ACS (Acute Coronary Syndrome) patients, 3 months of Dual Antiplatelet Therapy (DAPT) was non-inferior to 12 months.
This is a game-changer for high-bleeding-risk patients who need a ‘short-fuse’ recovery.
Superior Healing Profile: Optical Coherence Tomography (OCT) studies consistently show earlier and more uniform strut coverage compared to standard everolimus-eluting stents.
The observer’s stratregic take:
The industry is shifting from ‘Deliverability’ to ‘Vascular Health Restoration’.
The COMBO Plus is a benchmark for Scientific Branding.
By solving the ‘Late-Stent Thrombosis’ anxiety through accelerated endothelialization, OrbusNeich has moved the product from a commodity to a Strategic Safety Investment.
For clinicians handling complex, high-risk cases, this isn’t just about opening a vessel – it’s about ensuring it stays healthy.
The executive question:
Will you investing in ‘Active Biologics’? In a value-based care model, the device that heals fastest wins.”
Stay updated with Hemostasis Today.
-
May 9, 2026, 22:43Simon Ash: Gestational Thrombocytopenia and Maternal Risk at SOAPAM 2026
-
May 9, 2026, 22:18Rupam Manna: Thrombocytopenia in Oncology – Complete High-Yield Guide for Safe Chemotherapy Delivery
-
May 9, 2026, 22:12Muhammad Aasim Ali: Treatment Strategies for Chemotherapy-Induced Cytopenias
-
May 9, 2026, 16:38Joseph R. Shaw: Risk Stratification is Only Useful if It is Practical, Consistent, and Easy to Apply at the Bedside
-
May 9, 2026, 16:11Milad Abdalla: When 180,000 Becomes 45,000 – The EDTA Trap
-
May 9, 2026, 16:10Gertrud U. Rey: Describing the Mechanism That Causes VITT
-
May 9, 2026, 16:09Dima Shulkin: The Earliest Warning Sign of a Severe Heart Attack May Already Be in the CBC
-
May 9, 2026, 16:08Luisanna M. Sánchez: Selected for the ASH Clinical Research Training Institute
-
May 9, 2026, 16:07Maha Othman: Key Highlights from Southern Ontario Reproductive Biology